The Cytel blog keeps you up to speed with the latest developments in biostatistics and clinical biometrics.
‘A blend of courage and foolhardiness’: Marvin Zelen's 8 Predictions for the Future of Biostatistical Sciences
Ten years ago, in May 2005, world-renowned biostatistician Marvin Zelen was asked to deliver a keynote address before the Eastern Mediterranean Region of the Biometric Society. His address, entitled ‘Biostatisticians, Biostatistical Science and the Future,’  offered a reflection on the direction which the field at large would have to take, given the anticipated leaps in software and the rise of big data.
This included eight predictions on how short and longer term advances in technology would shape the field.
As we prepare to celebrate the annual Marvin Zelen Leadership Award in Statistical Science, this year awarded to Professor Nan Laird (Harvard University)   we can take a moment to re-examine the predictions and insights of Cytel's beloved friend and Board Member.
Where will the field of biostatistical sciences be ten years from now? Thirty years from now? How about one hundred years from now? It is perhaps a guessing game full of imprecise probabilities and chances for Bayesian updating.
The VALOR trial recently applied a promising zone design to a Phase 3 evaluation of Vosaroxin, a candidate for the treatment of relapsed/refractory acute myeloid leukemia. CMO Dr. Adam Craig reports that there were intial anxieties about financing a trial that required 800 patients. However, a promising interim look raised investors' confidence in the treatment's success, leading to a high-powered trial of 712 patients.
To view a YouTube video of Dr. Adam Craig talking about the Phase 3 VALOR trial, click below.